Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
Name
Lander_Activating mTOR.pdf
Size
1.4 MB
Format
Adobe PDF
Checksum (MD5)
2ad2f5f935130ca55c0c5b1b84188c6e
Author(s)
Wagle, N.
Grabiner, Brian C.
Van Allen, E. M.
Hodis, Eran
Jacobus, S.
Supko, J. G.
Stewart, M.
Choueiri, T. K.
Gandhi, L.
Cleary, J. M.
Date Issued
March 2014
Journal
Cancer Discovery
Publisher
American Association for Cancer Research
Citation
Wagle, N., B. C. Grabiner, E. M. Van Allen, E. Hodis, S. Jacobus, J. G. Supko, M. Stewart, et al. “Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib.” Cancer Discovery 4, no. 5 (March 13, 2014): 546–553.
Version
Author's final manuscript
Abstract
Understanding the genetic mechanisms of sensitivity to targeted anticancer therapies may improve patient selection, response to therapy, and rational treatment designs. One approach to increase this understanding involves detailed studies of exceptional responders: rare patients with unexpected exquisite sensitivity or durable responses to therapy. We identified an exceptional responder in a phase I study of pazopanib and everolimus in advanced solid tumors. Whole-exome sequencing of a patient with a 14-month complete response on this trial revealed two concurrent mutations in mTOR, the target of everolimus. In vitro experiments demonstrate that both mutations are activating, suggesting a biologic mechanism for exquisite sensitivity to everolimus in this patient. The use of precision (or “personalized”) medicine approaches to screen patients with cancer for alterations in the mTOR pathway may help to identify subsets of patients who may benefit from targeted therapies directed against mTOR.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Whitehead Institute for Biomedical Research
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1158/2159-8290.cd-13-0353
